Sarcoma medical oncologist at Dana-Farber
Boston, MA
Joined June 2009
- Tweets371
- Following287
- Followers947
- Likes1.4K
Authors of abstracts will be invited to submit proposals for $25,000 research grants.
binaytara.org/projects/confe…
Michael Wagner retweeted
FDA approves daraxonrasib for metastatic pancreatic cancer following landmark clinical trial led by @DanaFarber and Brian Wolpin, MD, MPH, of @DanaFarber_Hale
Michael Wagner retweeted
SARC046 is a Phase II trial studying nab-sirolimus in adults with progressing or symptomatic EHE, now enrolling patients at:
@DanaFarber
@MSKCancerCenter
@SitemanCancer
@StanfordCancer
Visit: clinicaltrials.gov/study/NCT…
Special shout outs to @SarcomaAlliance & @wagsmd!
Michael Wagner retweeted
🎗️ Celebrate 30 years of hope with Northwest Sarcoma Foundation! Give $30 for our "$30 for 30 Years" campaign—your gift supports patients, education, and research. No one should face sarcoma alone.
Donate: nwsarcoma.org #SarcomaAwareness #DragonslayersUnite #Sarcoma
Michael Wagner retweeted
Approximately 13,900 cases of soft tissue sarcoma and approximately 4,110 cases of bone and joint cancer are expected to be diagnosed in the U.S. Learn more during Sarcoma and Bone Cancer Awareness Month: brnw.ch/21x4fT6
Michael Wagner retweeted
During #SarcomaAwarenessMonth, Bilasan Hammo, MD, shares her experiences since being diagnosed with #EwingSarcoma at age 30 and why @DanaFarber’s Adolescent and Young Adult (AYA)-focused care matters. ➡️bit.ly/4vOhPUR
We need a similar study of GSI for desmoid fibromatosis.
Original Article: Continuous or Fixed-Duration Maintenance Therapy in Multiple Myeloma (phase 3 ENDURANCE trial) nej.md/3TlfOlb
Editorial: Time to Stop? Rethinking the Duration of Maintenance Treatment in Multiple Myeloma nej.md/4wo0Iu9
#Hematology
ALT A graph showing overall survival (intention-to-treat population). The graph compares indefinite-duration lenalidomide (blue line) with fixed-duration lenalidomide (gray line). The x-axis is labeled "Months since Second Randomization," and the y-axis is labeled "Percentage of Patients Alive." A "No. at Risk" table sits below the graph.
ALT A graph showing progression-free survival (intention-to-treat population). The graph compares indefinite-duration lenalidomide (blue line) with fixed-duration lenalidomide. The x-axis is labeled "Months since Second Randomization," and the y-axis is labeled "Percentage of Patients Free from Progression." A "No. at Risk" table sits below the graph.
Michael Wagner retweeted
I agree! Need to see more of it!
Here is a recent pub from Dr. Maitz and his veterinary team, testing Lattice SBRT in dogs 🐶 😍
Link in reply
Leaving Chicago after a productive ASCO26. Easily the best meeting was with Cody for the human-canine sarcoma alliance. 🐶 About 15% of dog cancers are sarcoma, a higher rate than in humans. Help dogs, help people. Better treatments for all.
Photo credit @Slade_Mellgard
Leaving Chicago after a productive ASCO26. Easily the best meeting was with Cody for the human-canine sarcoma alliance. 🐶 About 15% of dog cancers are sarcoma, a higher rate than in humans. Help dogs, help people. Better treatments for all.
Photo credit @Slade_Mellgard
SARC045 and SARC046 trial in progress posters next to each other. Coincidence? #ASCO26 @SARCtrials
Encouraging early results with TP53 R175H TCR cell therapy in multiple tumor types including pancreas cancer and a patient with leiomyosarcoma presented by Dr. Rishi Surana @DanaFarberNews ASCO26
DART study 🎯 showed responses in 31 (if I counted correctly) different rare tumor types with ipi+nivo. So important for patients with rare cancers. Amazing effort by @Dr_R_Kurzrock @PatelOncology @SWOG supported by @theNCI @NCIDirector #ASCO26
What can you do when native tumor antigens aren’t enough for checkpoint inhibitors? Force it to make more antigens with an ERAP1 inhibitor. #ASCO26
